№ lp_1_27211
File format: docx
Character count: 23374
File size: 79 KB
This document is a detailed histopathology reporting guide for soft tissue sarcomas, outlining the core and non-core elements for biopsy specimens, intended to standardize cancer reporting for clinical management.
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Organisation:
International Collaboration on Cancer Reporting
Document type:
Histopathology reporting guide
Subject:
Gastrointestinal stromal tumour (GIST)
Scope:
Pathology reporting of resection specimens for GIST
Exclusions:
Metastatic GIST specimens
Edition:
1st edition
Applicable staging system:
Pathological TNM staging
Evidence framework:
NHMRC levels of evidence
Intended users:
Pathologists reporting GIST resection specimens
Related publications:
Gastrointestinal Stromal Tumour (GIST) Histopathology Reporting Guide – Biopsy Specimens; Soft Tissue Sarcoma Histopathology Reporting Guide – Resection Specimens
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2019
Region / city:
Not specified
Theme:
Oncology
Document type:
Clinical Protocol
Authors:
Erin Rudzinski, MD; Bruce Pawel, MD; Armita Bahrami, MD; M. John Hicks, MD
Target audience:
Healthcare professionals involved in pediatric oncology
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
February 2019
Year:
2022
Protocol Version:
4.4.0.0
Protocol Posting Date:
March 2022
Required Use Date:
December 2022
Program:
CAP Laboratory Accreditation Program
Issuing Organization:
College of American Pathologists
Committees:
CAP Cancer Committee; CAP Pathology Electronic Reporting Committees
Authors:
Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO
Subject:
Pathologic examination and synoptic reporting of primary uterine sarcoma resection specimens
Tumor Types Covered:
Leiomyosarcoma; Adenosarcoma; Endometrial stromal sarcoma; Undifferentiated uterine/endometrial sarcoma
Excluded Tumor Types:
Carcinoma; Lymphoma
Applicable Procedures:
Total hysterectomy; Supracervical hysterectomy; Radical hysterectomy; Salpingo-oophorectomy; Omentectomy; Peritoneal biopsy; Peritoneal washing
Reporting Standard:
Synoptic reporting format with core and conditional data elements
Staging Standards Referenced:
AJCC-UICC 8; FIGO Cancer Report 2018
Intended Users:
Pathologists and laboratories participating in CAP accreditation
Year of publication:
2025
Receipt of originals:
10/27/2025
Acceptance for publication:
11/27/2025
DOI:
https://doi.org/10.56238/isevjhv4n6-002
Authors:
Fernanda Cristina Galerani Gualtieri Parpinelli; Augustin Malzac; Henrique Lucas Codognoto; Cristina Jardelino de Lima; Guilherme Banck; Diogo Melo Mendo
Type of document:
Narrative literature review
Field:
Oncology; Orthopedic Oncology
Subject:
Multidisciplinary management of osteosarcoma, chondrosarcoma, and Ewing sarcoma
Population focus:
Pediatric and young patients with primary malignant bone tumors
Study period covered:
2015–2025
Databases consulted:
PubMed; Scopus; Cochrane
Therapeutic approaches discussed:
Surgical resection (R0 margins); Neoadjuvant and adjuvant chemotherapy (MAP; VAC/IE); Radiotherapy; Proton therapy; Immune checkpoint inhibitors; CAR-T cell therapy
Molecular aspects:
EWS-FLI1 translocation; IDH1/IDH2 mutations; Circulating tumor DNA (ctDNA)
Imaging modalities:
MRI; CT; PET-CT
Keywords:
Osteosarcoma; Chondrosarcoma; Ewing Sarcoma; Targeted Therapy; EWS-FLI1; Biomarkers; Immunotherapy
Grant Name:
ANZSA 2023 SRG
Year:
2023
Organization:
ANZSA
Related Organization:
ASSG
Document Type:
Grant Application Form
Subject Area:
Sarcoma Research
Application Components:
Applicant Details, Project Description, Budget, Lay Summary, Supporting Documents
Submission Method:
Email submission
Required Attachments:
Curriculum Vitae; Letters of Recommendation or Support (optional)
Project Duration:
12 months
Contact Email:
[email protected]
Year:
2010–2025
Region / City:
Italy
Topic:
Molecular profiling of mesenchymal tumors
Document type:
Consensus paper supplement
Institution:
Italian Sarcoma Group
Audience:
Medical researchers, oncologists, pathologists
Methods:
Literature review, PubMed search, article screening
Number of articles reviewed:
2,699
Number of articles included in final analysis:
146
Additional publications considered:
December 31, 2024 – August 31, 2025
Filters applied:
Full text, clinical trials, guidelines, meta-analyses, observational studies, humans, English language
Search strategy:
Next-generation sequencing, genomic profiling, liquid biopsy, RNAseq, fusion panel, methylation
Reference list selection:
Most relevant articles according to journal guidelines
Systematic review type:
Consensus-based literature review
Screening process:
Title screening, abstract evaluation, full-text evaluation
Year:
2018
Region:
North America
Subject:
Cancer data collection, Soft tissue sarcoma, GIST, Thymoma
Document type:
Guidelines and Q&A
Organization:
NAACCR, AJCC, SEER, CoC
Author:
Not specified
Target audience:
Cancer registrars, clinical coders, oncology data specialists
Effective period:
Cases diagnosed 2018 onward
Date issued:
January 11, 2018
Related resources:
ICD-O 3 Coding Guidelines, FORDS 2016, SEER 2016 Coding Manual, STORE 2018
Year:
2023
Region / City:
Colchester
Topic:
Histopathology
Document Type:
User Guide
Organization / Institution:
Colchester Hospital
Author:
ESNEFT Pathology Service
Target Audience:
Hospital and community users of the Histopathology laboratory service
Period of Effectiveness:
Ongoing
Approval Date:
Not specified
Date of Changes:
Updated in 2023 (multiple changes mentioned)
Note:
Year
Theme:
Histopathology
Document type:
Template
Organization:
General Medical Council
Target audience:
Applicants for the Portfolio Pathway
Contextual description:
Template for mapping evidence to the CiPs for applicants to the Specialist Register in Histopathology.
Year:
2021
Region / City:
Global
Topic:
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Histopathology
Document Type:
Reporting Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Merlin T, Weston A, Tooher R
Target Audience:
Pathologists, Oncologists, Medical Researchers
Effective Period:
2021 onwards
Approval Date:
2021
Date of Changes:
June 2021
Note:
Year
Subject:
Quality Assurance, Histopathology
Document Type:
Protocol
Year:
2021
Organisation:
International Collaboration on Cancer Reporting
Document type:
Histopathology reporting guide
Subject:
Gastrointestinal stromal tumour (GIST)
Scope:
Pathology reporting of resection specimens for GIST
Exclusions:
Metastatic GIST specimens
Edition:
1st edition
Applicable staging system:
Pathological TNM staging
Evidence framework:
NHMRC levels of evidence
Intended users:
Pathologists reporting GIST resection specimens
Related publications:
Gastrointestinal Stromal Tumour (GIST) Histopathology Reporting Guide – Biopsy Specimens; Soft Tissue Sarcoma Histopathology Reporting Guide – Resection Specimens
Year:
2024
Note:
Region / city
Topic:
Oncology, Testicular Cancer
Document Type:
Reporting Guide
Organization / institution:
International Collaboration on Cancer Reporting (ICCR)
Target Audience:
Pathologists, Oncologists
Date of changes:
July 2024
Scope:
Retroperitoneal lymphadenectomy and metastasis excision specimens reporting
Keywords:
Testicular Cancer, Retroperitoneal Lymphadenectomy, Histopathology, Reporting, Staging, Prognosis
Hendry J, Fraser S, White J, Rajan P, Hendry DS (2015). Retroperitoneal lymph node dissection (RPLND) for malignant phenotype Leydig cell tumours of the testis:
a 10-year experience.
Latarius S, Leike S, Erb H, et al. (2023). Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure:
detailed real-life data of complications and additional surgical procedures in 295 cases.
Description:
A histopathology reporting guide detailing core and non-core elements for retroperitoneal lymphadenectomy specimens and their role in cancer staging and prognosis for testicular tumors.
Year:
2024
Region / City:
Letterkenny
Theme:
Healthcare, Medical Science, Employment Application
Document Type:
Application Form
Organization:
Health Service Executive
Author:
Health Service Executive
Target Audience:
Job Applicants, Healthcare Professionals
Period of Action:
October 2024
Approval Date:
N/A
Modification Date:
N/A